CytomX Therapeutics, Inc. Other Comprehensive Income (Loss), Net of Tax
CytomX Therapeutics, Inc. (CTMX) reported Other Comprehensive Income (Loss), Net of Tax of $1.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-27.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2019-02-27
- CytomX Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2017-12-31 was -$33.00K.
- CytomX Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2017-09-30 was $49.00K.
- CytomX Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2017-06-30 was -$10.00K, a 120.00% decline year-over-year.
- CytomX Therapeutics, Inc. other comprehensive income (loss), net of tax for the quarter ending 2017-03-31 was -$73.00K, a 168.87% decline year-over-year.
- CytomX Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2018 was $1.00K.
- CytomX Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2017 was -$67.00K, a 236.73% decline from fiscal 2016.
- CytomX Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2016 was $49.00K.
- CytomX Therapeutics, Inc. other comprehensive income (loss), net of tax for fiscal 2015 was -$76.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2018-12-31 | $1.00K 10-K · filed 2019-02-27 | |||
| 2017-12-31 | -$33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $16.00K derived: sum of 2 quarters · filed 2019-02-27 | $6.00K derived: sum of 3 quarters · filed 2019-02-27 | -$67.00K 10-K · filed 2019-02-27 |
| 2017-09-30 | $49.00K 10-Q · filed 2017-11-07 | $39.00K derived: sum of 2 quarters · filed 2017-11-07 | -$34.00K 10-Q · filed 2017-11-07 | -$67.00K derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | -$10.00K 10-Q · filed 2017-08-07 | -$83.00K 10-Q · filed 2017-08-07 | -$116.00K derived: sum of 3 quarters · filed 2019-02-27 | -$188.00K derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-03-31 | -$73.00K 10-Q · filed 2017-05-05 | -$106.00K derived: sum of 2 quarters · filed 2019-02-27 | -$178.00K derived: sum of 3 quarters · filed 2019-02-27 | -$128.00K derived: sum of 4 quarters · filed 2019-02-27 |
| 2016-12-31 | -$33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | -$105.00K derived: sum of 2 quarters · filed 2019-02-27 | -$55.00K derived: sum of 3 quarters · filed 2019-02-27 | $49.00K 10-K · filed 2019-02-27 |
| 2016-09-30 | -$72.00K 10-Q · filed 2017-11-07 | -$22.00K derived: sum of 2 quarters · filed 2017-11-07 | $82.00K 10-Q · filed 2017-11-07 | $16.00K derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-06-30 | $50.00K 10-Q · filed 2017-08-07 | $156.00K 10-Q · filed 2017-08-07 | $88.00K derived: sum of 3 quarters · filed 2018-03-07 | $81.00K derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-03-31 | $106.00K 10-Q · filed 2017-05-05 | $38.00K derived: sum of 2 quarters · filed 2018-03-07 | $31.00K derived: sum of 3 quarters · filed 2018-03-07 | $40.00K derived: sum of 4 quarters · filed 2018-03-07 |
| 2015-12-31 | -$68.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | -$75.00K derived: sum of 2 quarters · filed 2018-03-07 | -$66.00K derived: sum of 3 quarters · filed 2018-03-07 | -$76.00K 10-K · filed 2018-03-07 |
| 2015-09-30 | -$7.00K 10-Q · filed 2016-11-03 | $2.00K derived: sum of 2 quarters · filed 2016-11-03 | -$8.00K 10-Q · filed 2016-11-03 | |
| 2015-06-30 | $9.00K 10-Q · filed 2016-08-03 | -$1.00K 10-Q · filed 2016-08-03 | ||
| 2015-03-31 | -$10.00K 10-Q · filed 2016-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |